Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05296746
Title Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications

Her2-receptor negative breast cancer

Therapies

Ribociclib

Age Groups: adult | senior
Covered Countries FRA | ESP


No variant requirements are available.